Topic: Bristol-Myers Squibb Company
SAN DIEGO (Reuters) - A new type of diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca was effective in a two-year study but more bladder and breast cancers have been found in patients treated with the drug.In all studies so far ...
SAN DIEGO (Reuters) - A new type of diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca was effective in a two-year study, but the companies said more bladder and breast cancers have been seen in patients treated with the drug.In an ...
Drugmaker Bristol-Myers expected to focus on new drug approvals, more on horizon in 3Q reportBristol-Myers Squibb Co., the maker of popular blood thinners Plavix and Coumadin, is likely to spend some time trumpeting its latest acquisition, plus two recent drug approvals and ...
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone. "We are pleased to see the results from this Phase ...
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin ...
Bristol-Myers expected to focus on drug research progress, approval prospects in 2Q reportDrugmaker Bristol-Myers Squibb Co. is expected to focus on a raft of recent positive research data and plans to seek approval for several drugs when it reports its second-quarter results ...
Bristol-Myers sees big jumps in 1Q sales, profit, but lowers forecast on health overhaul costsDrugmaker Bristol-Myers Squibb Co. on Thursday reported double-digit jumps in first-quarter sales and profit, beating Wall Street expectations, but it lowered its 2010 profit forecast by a nickel ...
PRINCETON, N.J. & Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and ...
Titrate in increments of one tablet (using the tablet strength at which therapy was initiated) daily at 2-week intervals until adequate blood glucose control is achieved or maximum daily dosage of 2 g of metformin hydrochloride and 10 mg of glipizide is ...
Bristol-Myers, partner AstraZeneca get EU approval for diabetes drug Onglyza, rival for MerckDrugmaker Bristol-Myers Squibb Co. said Monday that its new diabetes drug, Onglyza, has been approved for sale in the European Union's 27 countries.That means Onglyza will compete with Merck & ...
Photo Gallery
From Around the Web
Video Gallery
-
Pfizer (PFE) and Bristol Myers Squibb ...
(05-21-08) Julie catches up with participants of the big pharma-sponsored ...2008-05-21 -
Company Profile: Bristol-Myers Squibb Company (NYS...
The company's blockbuster cardiovascular line-up includes heart disease drug ...2010-04-21 -
News Update: Bristol-Myers Squibb Co. Received ...
Bristol-Myers Squibb Co. (NYSE:BMY) got LEED Silver certification Wednesday ...2010-04-21
